Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

Katherine A Rauen¹, Lisa Schoyer², Lisa Schill², Beth Stronach², John Albeck³, Brage S Andresen⁴, Hélène Cavé⁵, Michelle Ellis⁶, Steven M Fruchtman⁷, Bruce D Gelb⁸, Christopher C Gibson⁹, Karen Gripp¹⁰, Erin Hefner¹¹, William Y C Huang¹², Maxim Itkin¹³, Bronwyn Kerr¹⁴, Corinne M Linardic¹⁵, Martin McMahon¹⁶, Beverly Oberlander¹⁷, Ethan Perlstein¹⁸, Nancy Ratner¹⁹, Leslie Rogers²⁰, Annette Schenck²¹, Suma Shankar³, Stanislav Shvartsman²², David A Stevenson²³, Edward C Stites²⁴, Philip J S Stork²⁵, Cheng Sun²⁶, Marc Therrien²⁷, Erik M Ullian²⁸, Brigitte C Widemann²⁹, Erika Yeh²⁸, Giuseppe Zampino³⁰, Martin Zenker³¹, William Timmer³², Frank McCormick^{28

33}

Affiliations

¹ Department of Pediatrics, University of California Davis, MIND Institute, Sacramento, California.
² RASopathies Network, Altadena, California.
³ Department of Pediatrics, University of California Davis, Davis, California.
⁴ Department of Biochemistry and Molecular Biology and the Villum Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark.
⁵ Genetics Department, Hôpitaux de Paris, Hôpital Robert Debré, Paris-Diderot University, Paris, France.
⁶ Noonan UK, London, United Kingdom.
⁷ Onconova Therapeutics, Newtown, Pennsylvania.
⁸ Departments of Pediatrics and Genetics and Genomic Sciences, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
⁹ Recursion Pharmaceuticals, Salt Lake City, Utah.
¹⁰ Departments of Division of Medical Genetics, AI duPont Hospital for Children, Wilmington, Delaware.
¹¹ Costello Syndrome Family Network, Creve Coeur, Illinois.
¹² Department of Chemistry, University of California Berkeley, Berkeley, California.
¹³ Department of Radiology, Penn Medicine, Philadelphia, Pennsylvania.
¹⁴ Department of Genetic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
¹⁵ Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
¹⁶ Departments of McMahon, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
¹⁷ Neurofibromatosis Network, Murrieta, California.
¹⁸ Perlara, South San Francisco, California.
¹⁹ Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
²⁰ CFC International, Roseburg, Oregon.
²¹ Departments of Ratner, Radboud University Medical Center, Nijmegen, Netherlands.
²² Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey.
²³ Department of Pediatrics, Stanford University, Palo Alto, California.
²⁴ Departments of Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California.
²⁵ Departments of Stork, Oregon Health & Sciences University, Portland, Oregon.
²⁶ Department of Stem Cell and Regenrative Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
²⁷ Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec, Canada.
²⁸ Department of Ophthalmology, Neuroscience Program, University of California, San Francisco, San Francisco, California.
²⁹ Departments of Peiatric Oncology Branch, National Cancer Institute, Center for Cancer Research, Pediatric Oncology Branch, Bethesda, Maryland.
³⁰ Departments of Department of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
³¹ Departments of Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany.
³² Departments of Cancer Therapy Evaluation Program, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland.
³³ Departments of McCormick, RAS Initiative, Frederick National Lab, Frederick, Maryland.

PMID: 30302932
PMCID: PMC6312476
DOI: 10.1002/ajmg.a.40632

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

Katherine A Rauen et al. Am J Med Genet A. 2018 Dec.

. 2018 Dec;176(12):2924-2929.

doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10.

Authors

Affiliations

¹ Department of Pediatrics, University of California Davis, MIND Institute, Sacramento, California.
² RASopathies Network, Altadena, California.
³ Department of Pediatrics, University of California Davis, Davis, California.
⁴ Department of Biochemistry and Molecular Biology and the Villum Center for Bioanalytical Sciences, University of Southern Denmark, Odense, Denmark.
⁵ Genetics Department, Hôpitaux de Paris, Hôpital Robert Debré, Paris-Diderot University, Paris, France.
⁶ Noonan UK, London, United Kingdom.
⁷ Onconova Therapeutics, Newtown, Pennsylvania.
⁸ Departments of Pediatrics and Genetics and Genomic Sciences, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
⁹ Recursion Pharmaceuticals, Salt Lake City, Utah.
¹⁰ Departments of Division of Medical Genetics, AI duPont Hospital for Children, Wilmington, Delaware.
¹¹ Costello Syndrome Family Network, Creve Coeur, Illinois.
¹² Department of Chemistry, University of California Berkeley, Berkeley, California.
¹³ Department of Radiology, Penn Medicine, Philadelphia, Pennsylvania.
¹⁴ Department of Genetic Medicine, Manchester University NHS Foundation Trust, Manchester, United Kingdom.
¹⁵ Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina.
¹⁶ Departments of McMahon, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
¹⁷ Neurofibromatosis Network, Murrieta, California.
¹⁸ Perlara, South San Francisco, California.
¹⁹ Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
²⁰ CFC International, Roseburg, Oregon.
²¹ Departments of Ratner, Radboud University Medical Center, Nijmegen, Netherlands.
²² Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey.
²³ Department of Pediatrics, Stanford University, Palo Alto, California.
²⁴ Departments of Integrative Biology Laboratory, Salk Institute for Biological Studies, La Jolla, California.
²⁵ Departments of Stork, Oregon Health & Sciences University, Portland, Oregon.
²⁶ Department of Stem Cell and Regenrative Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
²⁷ Department of Pathology and Cell Biology, University of Montreal, Montreal, Quebec, Canada.
²⁸ Department of Ophthalmology, Neuroscience Program, University of California, San Francisco, San Francisco, California.
²⁹ Departments of Peiatric Oncology Branch, National Cancer Institute, Center for Cancer Research, Pediatric Oncology Branch, Bethesda, Maryland.
³⁰ Departments of Department of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
³¹ Departments of Institute of Human Genetics, University Hospital Magdeburg, Magdeburg, Germany.
³² Departments of Cancer Therapy Evaluation Program, National Cancer Institute, Cancer Therapy Evaluation Program (CTEP), Bethesda, Maryland.
³³ Departments of McCormick, RAS Initiative, Frederick National Lab, Frederick, Maryland.

PMID: 30302932
PMCID: PMC6312476
DOI: 10.1002/ajmg.a.40632

Abstract

This report summarizes and highlights the fifth International RASopathies Symposium: When Development and Cancer Intersect, held in Orlando, Florida in July 2017. The RASopathies comprise a recognizable pattern of malformation syndromes that are caused by germ line mutations in genes that encode components of the RAS/mitogen-activated protein kinase (MAPK) pathway. Because of their common underlying pathogenetic etiology, there is significant overlap in their phenotypic features, which includes craniofacial dysmorphology, cardiac, cutaneous, musculoskeletal, gastrointestinal and ocular abnormalities, neurological and neurocognitive issues, and a predisposition to cancer. The RAS pathway is a well-known oncogenic pathway that is commonly found to be activated in somatic malignancies. As in somatic cancers, the RASopathies can be caused by various pathogenetic mechanisms that ultimately impact or alter the normal function and regulation of the MAPK pathway. As such, the RASopathies represent an excellent model of study to explore the intersection of the effects of dysregulation and its consequence in both development and oncogenesis.

Keywords: Costello syndrome; Legius syndrome; Noonan syndrome; RAS/MAPK; RASopathies; cardio-facio-cutaneous syndrome; clinical trial; neurofibromatosis type 1; signal transduction pathway; therapy.

PubMed Disclaimer

References

1. Rauen KA (2013). The RASopathies. Annual Review of Genomics and Human Genetics, 14, 355–369. - PMC - PubMed
1. Stephen AG, Esposito D, Bagni RK, & McCormick F (2014). Dragging Ras back in the ring. Cancer Cell, 25, 272–281. - PubMed
1. Tidyman WE, & Rauen KA (2016). Pathogenetics of the RASopathies. Human Molecular Genetics, 25, R123–R132. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

Affiliations

Proceedings of the fifth international RASopathies symposium: When development and cancer intersect

Authors

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials